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Objectives This study sought to assess the effect of baseline systolic blood pressure (SBP) and changes in SBP on the effec-
tiveness of treatment with fixed-dose combination of isosorbide dinitrate and hydralazine (FDC I/H) in patients
with heart failure (HF).
Background Low SBP is a risk factor for adverse outcomes in patients with HF. However, FDC I/H lowered SBP in the A-HeFT
(African-American Heart Failure Trial) and yet prolonged survival. Whether blood pressure (BP) lowering is critical
to the efficacy of FDC I/H and whether a low BP limits its effectiveness is unclear.
Methods The effects of FDC I/H on SBP and on mortality and hospitalization were compared in patients with a low or high
baseline SBP using multivariable Cox regression models. The interaction between the effect of treatment and
baseline SBP was examined.
Results Mean  SD baseline SBP in all of the patients was 126 18 mm Hg. Patients with baseline SBP equal to or below
the median (126 mm Hg) had features of more severe HF. Baseline SBP equal to or below the median was an inde-
pendent risk factor for death (hazard ratio [HR] 2.09; 95% confidence interval [CI] 1.02 to 4.29) or first hospitalization
for HF (HR 1.66; 95% CI 1.18 to 2.34). The FDC I/H treatment reduced BP in patients with SBP above the median but
not in patients with SBP below 126 mm Hg. The FDC I/H treatment was associated with a similar decrease in mortal-
ity or hospitalization for HF in patients with SBP below the median and above the median. The effects of FDC I/H on
mortality alone were also similar.
Conclusions In A-HeFT, patients with lower SBP had a greater risk but a similar relative benefit from the use of FDC I/H as
those with higher SBP. The FDC I/H treatment did not reduce SBP in patients with low SBP. An asymptomatic
low SBP should not be considered a contraindication to use of FDC I/H in patients with HF. (J Am Coll Cardiol
2007;49:32–9) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.04.109p
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ccepted April 17, 2006.ressure on risks of major cardiovascular events are well
stablished (2–4). In patients with heart failure (HF),
owever, low blood pressure is a manifestation of a low
ardiac output and is associated with an increase in mortality
5–7). Indeed, vasodilator drugs that increase cardiac output
See page 40
ay further reduce blood pressure in some but not all patients
8). In the V-HeFT (Vasodilator Heart Failure Trial) study,
he vasodilator combination of isosorbide dinitrate and hydral-
zine added to background therapy with digoxin and diuretics
id not significantly lower blood pressure but improved survival
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January 2/9, 2007:32–9 Low Blood Pressure and FDC I/H Therapy9). Furthermore, prazosin, an alpha-adrenergic receptor
locker, lowered blood pressure but did not improve survival
9). In the recently reported A-HeFT (African-American
eart Failure Trial) study, the fixed-dose combination of
sosorbide dinitrate and hydralazine (FDC I/H) therapy re-
ulted in a modest blood pressure reduction and profound
eduction in mortality and morbidity when added to back-
round therapy that included angiotensin-converting enzyme
nhibitors (ACE-I), angiotensin receptor blockers (ARB),
nd/or beta-blockers (10). The benefits of FDC I/H and other
ntihypertensive regimens on outcome has been attributed to
he blood pressure lowering effect (11,12) and not to any
pecific direct action of the drugs on vascular and cardiac
tructure and function.
However, concerns about the hypotensive effects of med-
cations with vasodilator actions often limit their use in
atients with HF, especially in those with a low pretreat-
ent blood pressure. Indeed, some physicians hesitate to
rescribe these drugs to avoid reducing blood pressure
urther. Whether FDC I/H worsens hypotension, particu-
arly in patients with low pretreatment blood pressure, and
hether an initial low systolic blood pressure (SBP) or
ecrease in blood pressure related to the use of FDC I/H
imits its effectiveness in patients with HF has not been
valuated.
The purpose of this investigation was to analyze the
ffects of baseline blood pressure and changes in blood
ressure on the effectiveness of treatment with FDC I/H on
orbidity and mortality in the A-HeFT study. First, we
onfirmed that a lower baseline SBP was independently
ssociated with increased risk of morbidity and mortality.
hen the interaction between the effects of treatment and
aseline SBP controlling for several other known prognostic
ariables was examined. Changes in SBP with FDC I/H or
lacebo were related to subsequent morbidity and mortality.
inally, to determine whether adjusting for any potentially
eleterious decreases in blood pressure would enhance the
pparent beneficial effects of FDC I/H, we examined how
ontrolling for changes in SBP affected the beneficial effect
f treatment on morbidity and mortality.
ethods
tudy design and patient selection. The details of the
-HeFT study have been published previously (10). Briefly,
he A-HeFT study was a randomized, placebo-controlled,
ouble blind trial in self-identified black patients recruited at
69 centers in the U.S. The trial evaluated the efficacy of FDC
/H versus placebo in 1,050 patients with New York Heart
ssociation functional class III to IV HF. Patients 18 years and
lder with a left ventricular ejection fraction (LVEF)35% or
VEF45% with a left ventricular internal diastolic diameter
2.9 cm/m2 of body surface area or 6.5 cm by echocardi-
graphy within the 6 months preceding randomization were
ligible for screening. Exclusion criteria included uncontrolled
ypertension defined as an SBP persistently 160 mm Hg or piastolic blood pressure 95 mm
g. The protocol did not specify a
inimum required SBP at base-
ine; however, patients with symp-
omatic hypotension were ex-
luded. Randomization to either a
xed-dose combination of FDC
/H or a placebo added to back-
round therapy was stratified ac-
ording to use of a beta-blocker in
ackground therapy. Therapy was
nitiated at 1 tablet containing ei-
her placebo or 20 mg isosorbide
initrate and 37.5 mg hydralazine
ydrochloride 3 times daily. Up-
itration of the dose to 2 tablets 3
imes daily (120/225 mg of FDC
/H daily) was scheduled after 3 to
days, depending on tolerability as assessed by telephone. The
rst follow-up visit was scheduled for 3 months, and follow-up
ontinued at 3-month intervals for up to 18 months. At
aseline and at each follow-up visit, a single measurement of
lood pressure was recorded in the supine position using the
uff method.
The primary efficacy end point for the trial was a novel
omposite score weighting all-cause mortality, first hospital-
zation for HF, and change in the effect of HF on quality of life
s measured by the Minnesota Living With Heart Failure
uestionnaire at 6 months (10).
ata analysis. Baseline variables were compared using the
-sample t test for quantitative variables and Fisher exact test
or categorical variables. Time-to-events in various groups were
escribed by Kaplan-Meier curves. Cox proportional hazards
egression models were used to assess the association between
ime to death from any cause and baseline SBP, changes in
BP during the first 3 months of follow-up, and treatment
ith FDC I/H. Baseline SBPs were initially grouped into
uartiles to examine whether baseline SBP was linearly related
o the mortality and hospitalization hazards, and to examine
he effects of FDC I/H on SBP. The quartile analysis indicated
hat the relationships between baseline SBP and hazards were
ot linear. We did not attempt to fit nonlinear models of SBP
s a continuous variable. Subsequent tests for interactions
etween the effects of FDC I/H and baseline SBP and effect
odification by changes in SBP used the median baseline SBP
o group patients. Median groupings were used to enhance
tatistical power and also because the effects of SBP were
imilar in the 2 quartiles below the median and in the 2
uartiles above the median. Analyses were repeated using time
o first hospitalization for HF or death as the dependent
ariable. All of the regression models included baseline age,
ody mass index, heart rate, serum sodium, creatinine, uric
cid, hemoglobin, logarithm of the brain natriuretic peptide
oncentration (measured in 649 of the 1,050 subjects), LVEF,
innesota Living With Heart Failure questionnaire score,
Abbreviations
and Acronyms
ACE-I  angiotensin-
converting enzyme inhibitor
ARB  angiotensin
receptor blocker
CI  confidence interval
FDC I/H  fixed-dose
combination of isosorbide
dinitrate and hydralazine
HF  heart failure
HR  hazard ratio
LVEF  left ventricular
ejection fraction
SBP  systolic blood
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Low Blood Pressure and FDC I/H Therapy January 2/9, 2007:32–9brillation, and use of an ACE-I or ARB, beta-adrenergic
eceptor blocker, spironolactone, or diuretics as covariates. The
BPs in the 2 treatment groups were compared at each time
oint using a 2-sample t test. SAS statistical software (version
.2, SAS Institute Inc., Cary, North Carolina) was used for all
nalyses. A p value 0.05 was considered significant without
djustment for making multiple comparisons for this secondary
nalysis of data from a clinical trial.
esults
atient characteristics. The mean  SD of the SBP at
aseline was 126  18 mm Hg (n  1,050). Baseline
haracteristics of patients with SBP above and below the
edian value of 126 mm Hg are subgrouped by treatment and
Baseline Characteristics by Median SBP and Tre
Table 1 Baseline Characteristics by Median
SBP <126 mm
FDC I/H
(n  256)
Demographics
Age (yrs) 55 12
Male (%) 61
Blood pressure (mm Hg)
Systolic 113 10
Diastolic 73 9
Mean 86 8
Heart rate (beats/min) 74 13
Cause of heart failure (%)
Ischemic heart disease 24
Hypertensive 32
Idiopathic 29
Valvular 4
Other 11
NYHA functional class (%)
III 96
IV 4
Qualifying LVIDD (cm) 6.62 0.91
Qualifying LVEF (%) 23.4 7.3
Diabetes mellitus (%) 40
Atrial fibrillation (%) 17
MLHFQ score 55 24
LnBNP (pg/ml) 4.80 1.52
Body mass index (kg/m2) 32 8
Serum sodium (mEq/l) 139 3
Serum creatinine (mg/dl) 1.24 1.2
Uric acid (mg/dl) 8.8 2.3
Hemoglobin (g/dl) 13.3 1.6
Baseline medications (%)
Diuretic 91
ACE-I or ARB 93
Beta-blocker 84
Digoxin 61
Spironolactone 48
Calcium channel blocker 14
Values are mean  SD. *p  0.05. †p  0.01.
ACE-I  angiotensin-converting enzyme inhibitor; ARB  angiotensiand hydralazine; LnBNP log brain natriuretic peptide; LVEF left ventricular
MLHFQ  Minnesota Living with Heart Failure Questionnaire; NYHA  New Yompared in Table 1. Patients with SBP equal to or below the
edian had features of more severe HF with lower LVEF,
igher LV internal diameters in diastole, higher prevalence of
trial fibrillation, and poorer quality of life than those with an
BP above the median. Patients with a lower SBP were also
ore likely to be male and to be treated with diuretics, digoxin,
nd spironolactone, and less likely to receive calcium channel
lockers. Patients with a higher SBP were more likely to have
heir HF attributed to hypertension.
Above the median, baseline mean SBPs averaged 141 11
m Hg and 141  10 mm Hg in the FDC I/H and placebo
reatment groups, respectively. Most other patient characteris-
ics were also similar in these FDC I/H and placebo groups,
lthough the percentage of male patients was higher and
ent Group (n  1,050)
and Treatment Group (n  1,050)
 537) SBP >126 mm Hg (n  513)
Placebo
n  281)
FDC I/H
(n  262)
Placebo
(n  251)
55 13 58 13 59 13
67 51 60*
11 10* 141 11 141 10
70 9† 82 9 82 9
84 8† 102 8 101 8
73 11 74 12 73 11
22 22 24
30 48 46
34 20 21
3 1 3
11 8 7
95 98 95
5 2 5
.69 0.97 6.31 0.83 6.31 0.87
2.5 6.9 25.3 6.5 25.7 6.7
31* 50 44
20 14 16
54 25 47 26 47 26
.05 1.43 4.85 1.39 4.91 1.40
32 8 31 8 32 9
39 3 140 3 140 3
.32 1.2 1.23 1.1 1.23 1.1
8.7 2.7* 7.9 2.1 7.8 2.3
3.3 1.8 13.3 1.7 13.2 2.0
96* 91 89
93 91 93
80 83 84
66 56 55
45 32 30
12 28 28
tor blocker; FDC I/H  fixed-dose combination of isosorbide dinitrateatm
SBP
Hg (n
(
1
6
2
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n recep
ejection fraction; LVIDD left ventricular internal diastolic diameter;
ork Heart Association; SBP  systolic blood pressure.
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January 2/9, 2007:32–9 Low Blood Pressure and FDC I/H Therapyiabetes mellitus tended to be less prevalent in the placebo
roup. The mean SBP in patients below the median were 113
10 mm Hg and 111  10 mm Hg (p  0.05) in the FDC
/H and placebo treatment groups, respectively. Use of a
iuretic was less prevalent, and diabetes mellitus was more
revalent in this FDC I/H group compared with the placebo
roup.
aseline SBP related to morbidity and mortality. Unad-
usted time-to-event curves within quartiles of baseline SBP
re shown in Figure 1. The risk of mortality alone and
ortality or first hospitalization for HF were similar in the
upper quartiles and increased in the lower quartiles. The
nequal spacing between the curves representing quartiles of
BP suggests that SBP is not linearly related to the risk
hazard) of death or hospitalization for HF. Adjusted
azard ratios (HRs) for morbidity and mortality for groups
efined by baseline SBP are shown in Table 2. The adjusted
isks of mortality and mortality or the first hospitalization
or HF in the quartile with a baseline SBP above 140 mm
g were not significantly different from the reference
Adjusted Hazard Ratios (95% Confidence Intervaand Mortality for P tients Grouped by Baseline
Table 2 Adjusted Hazard Ratios (95% Confidand Mortality for Patients Grouped
Systolic Blood
Pressure (mm Hg)
Number of
Patients
Quartiles
112 179
112 and 126 139
126 and 140 179
140 129
Median
126 318
126 308
Figure 1 Effect of Baseline SBP on Mortality and Morbidity
Kaplan-Meier curves for mortality (left) and for mortality or the first hospitalizationSee Data Analysis section for list of covariates in the Cox regression model (nuartile with SBP ranging from over 126 to 140 mm Hg.
owever, the risk of hospitalization for HF or death was
ignificantly greater in the quartile with SBP 112 mm Hg
nd in the quartile with SBP112 mm Hg to 126 mm Hg.
he mortality risk was also significantly greater when the
aseline SBP was 112 mm Hg compared with the
eference quartile (SBP 126 and 140 mm Hg), and the
isk tended to be higher in the quartile with SBP ranging
rom 112 to 126 mm Hg. Collapsing quartiles above and
elow the median to increase precision, patients with a
aseline SBP below the median of 126 mm Hg had a
ignificantly increased risk of death (HR 2.09, 95% confi-
ence interval [CI] 1.02 to 4.29) and risk of death or first
ospitalization for HF (HR 1.66, 95% CI 1.18 to 2.34)
ompared with those with an SBP above 126 mm Hg.
hus, a lower baseline SBP was an independent risk factor
or morbidity and mortality.
ffect of baseline SBP on effectiveness of treatment.
verall, FDC I/H caused a 43% reduction in all-cause
ortality (HR 0.57, 95% CI 0.37 to 0.89) and a 37%
r Morbiditylic Blood Pressure
Interval) for Morbidity
seline Systolic Blood Pressure
ortality
Mortality or First Heart Failure
Hospitalization
.03–6.51)* 1.90 (1.23–2.94)†
.60–4.89) 1.64 (1.03–2.63)*
ence group Reference group
.36–3.46) 1.19 (0.70–2.03)
.02–4.29)* 1.66 (1.18–2.34)†
ence group Reference group
art failure (right), by quartiles of baseline systolic blood pressure (SBP).l) foSysto
ence
by Ba
M
2.59 (1
1.71 (0
Refer
1.12 (0
2.09 (1
Referfor he 626 with all covariates). *p  0.05. †p  0.01.
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Low Blood Pressure and FDC I/H Therapy January 2/9, 2007:32–9eduction in mortality or first hospitalization for HF (HR
.63, 95% CI 0.49 to 0.81) (10). When baseline SBP and
ther covariates were included in a Cox regression model,
he effects of FDC I/H on mortality or morbidity were
ot different in patients with a baseline SBP below or
bove the median of 126 mm Hg (Fig. 2). The FDC I/H
reatment was associated with a 67% decrease in mortality
n patients with an SBP below the median (HR 0.33, 95%
I 0.13 to 0.85) and a 48% decrease in mortality in
atients with an SBP above the median (HR 0.52, 95%
I 0.15 to 1.80) (interaction p  0.59). Similarly, the
ffects of FDC I/H on mortality or first hospitalization
or HF in patients with SBP below the median (HR 0.61,
5% CI 0.39 to 0.92) and above the median (HR 0.60,
5% CI 0.35 to 1.02) did not differ (interaction p  0.98)
Fig. 2).
ffect of treatment on SBP. Overall, treatment with FDC
/H caused a significant decrease in blood pressure through-
ut the trial (Fig. 3). The reduction in SBP was evident at
he 3-month visit, averaging 3.2 mm Hg compared with
lacebo (p  0.001) and remained stable over time. The
hange in SBP with FDC I/H by quartiles of baseline SBP
s shown in Table 3 and Figure 4. Compared with placebo,
reatment with FDC I/H did not lower SBP in the lower
quartiles (112 and 112 and 126 mm Hg). In fact,
he mean SBP increased in both groups, as one might expect
ith regression to the mean. Because the use of vasodilators
ight be most problematic for patients with an extremely
ow SBP, we also compared the response to FDC I/H
mean SBP  95 mm Hg; n  31) versus placebo (mean
BP  95 mm Hg; n  48) in the 79 patients whose
aseline SBP was100 mm Hg and found similar increases
n SBP (Fig. 4, bottom panel). A decrease in SBP was seen
Figure 2 Effect of FDC I/H Treatment on Mortality
and Morbidity by Median Baseline SBP
Effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine
(FDC I/H) treatment on mortality and morbidity in patients above or below the
median baseline systolic blood pressure (SBP) shown as point estimates of
the hazard ratios (HR) with 95% confidence intervals (CI). HF  heart failure.n the patients in the 2 higher quartiles, and FDC I/Haused a greater decrease in SBP than placebo at the
-month visit.
When patients were grouped by the median SBP at
aseline, the mean SBP increased at 3 months in the group
ith SBP below the median in both treatment groups,
lthough the SBP tended to increase less in the FDC I/H
roup than the placebo group (1.5 vs. 4.1 mm Hg, p 
.06). In contrast, SBP decreased after 3 months in patients
ith a baseline SBP above the median, with a significantly
reater decrease in the FDC I/H versus the placebo group
7.9 vs. 2.3 mm Hg, p  0.002). Interestingly, the daily
ose of the FDC I/H received by the patients in the groups
bove or below the median baseline SBP was the same (4.4
2.1 tablets vs. 4.4  2.0 tablets).
At the 3-month visit, dizziness was reported more
requently in the FDC I/H group (24.6%) than in the
lacebo group (8.9%, p  0.001). Reports of postural
ypotension were infrequent (0.6%) in both groups.
yncope occurred slightly more frequently in the FDC
/H group (2% vs. 1% for placebo, p  0.14). During the
rst 3 months, study medication was permanently dis-
ontinued in 2 subjects in each group because of symp-
omatic hypotension, and only 1 of these subjects (FDC
/H group) had a baseline SBP 100 mm Hg. No
ubjects permanently discontinued study medication be-
ause of renal dysfunction or acute renal failure during
he first 3 months. Of the patients who permanently
iscontinued study medications for any reason, only 5%
Figure 3 Time Course of Mean SBP and DBP
Change in the Placebo and FDC I/H Groups
Note that blood pressure decreased in the active treatment group soon after
starting treatment, with no further change in blood pressure over time. The p
values compare changes between treatment groups: *p  0.05; **p  0.01.
DBP  diastolic blood pressure; FDC I/H  fixed-dose combination of isosor-
bide dinitrate and hydralazine; SBP  systolic blood pressure.
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January 2/9, 2007:32–9 Low Blood Pressure and FDC I/H Therapyad a baseline SBP 100 mm Hg. There were 6 deaths
nd 31 hospitalizations for HF in the FDC I/H group
nd 5 deaths and 51 hospitalizations for HF in the
lacebo group during the first 3 months.
hanges in SBP related to morbidity and mortality.
ontrolling for baseline SBP and other covariates and ignoring
ssigned treatment, change in SBP from baseline to 3 months
n the group with baseline SBP above the median was
ositively associated with an increase in mortality (HR 1.04,
ffects of FDC I/H Versus Placebo on SBP After Three Months by
Table 3 Effects of FDC I/H Versus Placebo on SBP After Three
Q
<112 >112 and
FDC I/H Placebo FDC I/H
Number of patients 122 157 133
Mean SBP 105 7 104 7 120 3
Mean change 4.8 5.9 1.6
p  0.05. †p  0.01, FDC I/H versus placebo.
Abbreviations as in Table 1.
Figure 4 Change in Mean SBP in Baseline SBP
Quartiles and in Baseline SBP <100 mm Hg
In the fixed-dose combination of isosorbide dinitrate and hydralazine (FDC I/H)
group, blood pressure (BP) decreased in the 2 highest systolic blood pressure
(SBP) quartiles and increased in the lowest SBP quartile and in subjects with
baseline systolic BP 100 mm Hg, but did not change in the second lowest
SBP quartile. There were 79 subjects with baseline systolic BP 100 mm Hg
(mean SBP in FDC I/H group 95.0  5.0 mm Hg, n  31, and in placebo
group 95  5.4 mm Hg, n  48). The p values compare changes between
treatment groups: *p  0.05; **p  0.01.p5% CI 1.00 to 1.08, p 0.05) but not in combined morbidity
nd mortality (HR 1.0, 95% CI 0.99 to 1.02). Changes in SBP
n the group with baseline SBP below the median were not
ssociated with mortality (HR 0.99, 95% CI 0.96 to 1.02) or
orbidity (HR 1.0, 95% CI 0.99 to 1.02).
ffects of treatment adjusted for change in SBP. Con-
rolling for baseline covariates, the effect of FDC I/H on the
isk of death in patients with an SBP above the median was
ot greatly enhanced when the change in SBP (a decrease
n average) was added to the regression model (HR 0.52,
5% CI 0.15 to 1.80 vs. HR 0.49, 95% CI 0.13 to 1.80).
imilarly, the risk of death in patients with an SBP below
he median was not affected when the change in SBP (an
ncrease on average) was added to the regression model (HR
.33, 95% CI 0.13 to 0.86 vs. HR 0.33, 95% CI 0.13 to
.87). Likewise, the effects of FDC I/H on time to first
ospitalization or death also were not altered substantially
hen the 3-month change in SBP was added to the
egression model for patients above the median baseline
BP (HR 0.60, 95% CI 0.35 to 1.02 vs. HR 0.55, 95% CI
.32 to 0.95) or below the median SBP (HR 0.60, 95% CI
.39 to 0.92 vs. HR 0.58, 95% CI 0.38 to 0.90). These data
uggest that the effect of FDC I/H on blood pressure did
ot influence its effectiveness in reducing mortality or
orbidity, irrespective of whether the baseline SBP was low
r high.
iscussion
his report confirms that low SBP is independently asso-
iated with an increase in the risk of hospitalization and
ortality in patients with moderate to severe HF, probably
ecause low blood pressure in this setting is a manifestation
f a low cardiac output. The increased risk was observed in
atients with an SBP below the median of 126 mm Hg, and
he risk tended to increase in a nonlinear manner. The
eneficial effects of FDC I/H compared with placebo for
educing mortality and hospitalization for HF or mortality
ere similar in patients with a baseline SBP above or below
26 mm Hg. Interestingly, FDC I/H did not reduce SBP in
atients with the lowest pretreatment values, including the
uartile with an SBP112 mm Hg, or even the subgroup with
n SBP100 mm Hg. In patients with a baseline SBP126
m Hg, FDC I/H did reduce the blood pressure more than
iles of Baseline SBP
ths by Quartiles of Baseline SBP
es of Baseline SBP (mm Hg)
>126 and <140 >140
cebo FDC I/H Placebo FDC I/H Placebo
1 156 136 106 113
 3 134 4 133 4 151 10 151 8
1.6 5.6† 0.2 11.2* 5.3Quart
Mon
uartil
<126
Pla
12
120lacebo, as expected. However, changes in SBP during the first
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ffectiveness.
We believe these findings have important implications for
linicians treating patients with moderate to severe HF,
articularly those with low initial SBP. The observation that
lood pressure did not decrease in the group with low initial
BP, despite the use of the same dose of FDC I/H as in
atients with high SBP, challenges the belief that vasodila-
ors are deleterious in patients with low SBP. In fact, the
ata suggest that vasodilator therapy can usually be well
olerated by patients with severe HF, and that low blood
ressure should not preclude a trial of these agents, which seem
o offer a benefit to all patients. Admittedly, there were too few
atients in this clinical trial with an SBP below 100 mm Hg to
e assured that most would tolerate FDC I/H and not have
eleterious effects caused by a decrease in blood pressure.
ecause patients with a low initial SBP have greater risk and
he relative risk reduction with the use of FDC I/H was similar
egardless of SBP, patients with a low SBP would be expected
o derive the greatest absolute benefit from this treatment.
Although this study was not designed to address the
easons that FDC I/H did not lower blood pressure in
atients with a low pretreatment SBP, an appreciation of
he basic hemodynamics abnormalities in HF may help
xplain these observations. In the failing heart, a low stroke
olume threatens the arterial blood pressure and leads to a
aroreceptor-mediated activation of several neurohormones
hat help to preserve blood pressure by increasing arterial
mpedance (13). The increase in impedance is, however,
eleterious to the failing heart, and further reduces the
troke volume, worsening hypotension. Vasodilators such as
odium nitroprusside reverse the functional abnormalities
cutely by improving stroke volume and may increase blood
ressure (7). Thus, the vasodilator effects of FDC I/H
robably lowered arterial impedance of patients with the
owest SBP, who would be expected to have the highest
mpedance, and increased cardiac output. Furthermore, over
6-month period, use of FDC I/H was also associated with a
avorable effect on LV remodeling with a significant increase in
VEF (14), similar to the effect of other vasodilators such as
CE-I and ARBs (15,16). Thus, the dual effects of lowering
mpedance and improving LV structural remodeling might
ave contributed to the lack of deleterious effects of FDC I/H
n hemodynamics and subsequently to improved morbidity
nd mortality.
The decrease in blood pressure observed in the overall
-HeFT study population in response to FDC I/H was
trikingly different than the experience in the V-HeFT
tudy, in which blood pressure was not reduced by the drug
ombination. Because in the V-HeFT study the drug was
dministered in the absence of background neurohormone-
nhibiting therapy, it is likely that the blood pressure
eduction in the A-HeFT study resulted from the inhibiting
ffect of the background therapy on reflex vasoconstriction
nd cardiac stimulation. The difference might also be due to
ifferent drug formulations used in the 2 studies. Theortality reduction in the A-HeFT study (10) and in the
etrospective analysis of a small number of black subjects in
he V-HeFT study (17) further suggests that blood pressure
eduction is not a prerequisite for the favorable effect of the
xed-dose drug combination. Indeed, this analysis suggests
hat deceases in SBP observed in patients with a baseline
BP over 126 mm Hg might be deleterious, although they
id not influence the beneficial effects of FDC I/H.
In conclusion, the results of this study suggest that
atients with a low SBP can benefit from FDC I/H therapy
ithout an inordinate risk of deleterious hypotension. These
atients derive a similar benefit from FDC I/H therapy as
hose with normal or high pretreatment blood pressures.
atients with low blood pressure are at the highest risk, and
herefore are at the greatest need for aggressive therapy.
udicious use of FDC I/H in such patients is likely to
roduce an even greater absolute benefit than in those with
igher blood pressures. However, the data were not suffi-
ient to determine whether these findings generalize to
atients with an SBP well below 100 mm Hg. Regardless,
lood pressure reduction is neither an independent contrib-
tor to nor does it counteract the favorable effects of FDC
/H on hospitalization and mortality, and it cannot be used
s a surrogate for efficacy.
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